Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023
Up To Nine Adalimumab Biosimilars to Launch In Key Year
Dec 03 2020
•
By
Dean Rudge
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock
More from Biosimilars
More from Products